News
A study discovers new clues about the persistence of S. aureus in the hospital environment
A group from IDIBELL and the Bellvitge University Hospital has shown that a genetic variant of the bacterium would be associated with higher production of biofilm, a self-protection system that allows it to persist in the environment.
Let’s Tandem: Research Works
So far, the collaboration between IDIBELL and the Institut Bellvitge has allowed six students to carry out their research work at the IDIBELL facilities and see first-hand the work carried out there.
The generation of a stem cell-derived neurofibroma model opens the door to new treatments development
Neurofibromas are tumors of the peripheral nervous system, which develop in people with a hereditary disease, and they are the main cause of death among those people.
Two naturally occurring antibodies are responsible for the deterioration of valvular heart implants of animal origin
A study just published in the journal Nature Medicine, led has discovered that two antibodies naturally present in humans are responsible for triggering the immune response that causes the deterioration of heart implants of animal origin
The histology of liver metastases from colon cancer could influence immunotherapy
A study by IDIBELL and ICO in collaboration with Uppsala University analyzes antitumor immune activity in encapsulated metastases compared to unencapsulated ones.
The Biomedical Cluster receives the visit of Cristóbal Belda, director of the Carlos III Health Institute
The initiative wants to promote and consolidate this ecosystem located in the south of the Barcelona metropolitan area with the creation of new infrastructures and new services
The relevance of our female mentors
Today, February 11th is the International Day of Women and Girls in Science, and we want to highlight the importance of having mentors.
Convalescent plasma treatment against COVID-19 is not effective
The study shows no differences in complications that require hospitalization between people with COVID-19 who received intravenous plasma infusion and those who did not.